Companies track R&D KPIs because the alternative is genuinely dangerous: pharmaceutical R&D productivity fell roughly 100-fold between 1950 and 2010, a well-documented trend known as Eroom's Law, driven not by a lack of effort but by systemic inefficiencies that only show up when the right metrics are actually being measured. Yet most organizations trying to track that performance are working from a broken foundation. Only 24% of R&D teams use enterprise-wide systems to track metrics at all, and the ones that don't consistently report more difficulty standardizing data than those that do.
Why R&D productivity keeps eroding despite record spending
The scale of the underlying problem explains why KPI discipline matters so much. Pharmaceutical R&D intensity now exceeds 25% of revenue for the industry, more than eight times the 2 to 3% average across all US industries, and the top companies by spend now collectively invest well over $150 billion annually. Despite that investment, drug development costs have climbed to roughly $2.2 billion per approved compound, with 90% of drug candidates entering clinical development still failing to reach approval.
There's a genuine counterpoint worth acknowledging: some analyses show the trend has started reversing since around 2010, with the industry producing measurably more new molecular entities per billion dollars of R&D spending in recent years than it did at the low point. But that reversal came specifically from teams that got sharper about tracking success rates and cutting underperforming programs earlier, which is exactly the KPI discipline most organizations still lack.
The four structural problems behind bad metrics tracking
Most R&D organizations that struggle with performance measurement run into the same four failure points, and they compound each other rather than existing in isolation.
Nobody agrees on which KPIs actually matter. Teams frequently lack familiarity with the metrics most relevant to their specific business context, which means they either track generic, low-value numbers or track nothing consistently at all.
The underlying data is scattered and unstructured. Metrics can't be reliably tracked when the data feeding them lives across disconnected spreadsheets, personal notebooks, and siloed departmental systems, since there's no consistent source of truth to pull from.
The financial impact of R&D changes gets lost. Organizations frequently fail to connect performance improvements or setbacks back to actual bottom-line outcomes, which means KPI tracking becomes an internal reporting exercise rather than a tool that actually informs resource allocation.
The tooling to support any of this doesn't exist. Without dedicated systems capable of capturing, standardizing, and reporting on R&D data at scale, even a well-designed KPI framework has nowhere reliable to live.
Why KPIs matter beyond internal reporting
KPIs do more than satisfy an internal reporting requirement. They function as an audit trail for R&D spending in the same way financial records do, giving both the department and the wider organization a clear, quantifiable view of the value R&D generates over time. That structure is also what allows benchmarking against competitors and peers in the same industry, turning "how is R&D doing" from a subjective impression into an answerable, comparable question.
Input metrics versus output metrics
The starting point for any KPI framework is understanding the difference between what goes into R&D and what comes out of it, since the two require fundamentally different measurement approaches.
Input metrics are typically the more straightforward of the two: time and cost invested in R&D, usually expressed as quantitative values that track changes relative to output. Output metrics are messier by nature. They capture what the department has actually produced, project outcomes, successful launches, improved formulations, and because that value isn't always directly quantifiable, teams often rely on proxy measures like a 1-to-10 rating scale rather than a single hard number.
Evaluating both against a project's quality, quantity, and time impact is what turns raw input and output data into something actually useful for decision-making, rather than just two disconnected sets of numbers.
The seven categories worth tracking
Once an organization understands its input and output metrics, the next step is mapping them against broader performance categories that connect R&D activity to company-wide objectives: innovation metrics, time-to-market metrics, financial metrics, cost metrics, safety and regulatory compliance metrics, product improvement metrics, and talent and service metrics.
Which of these matter most depends heavily on what's actually within the R&D team's control versus what's shaped by external factors like market conditions or regulatory timelines, since holding a team accountable for metrics they can't meaningfully influence undermines the entire point of tracking performance in the first place.
What actually needs to be in place before any of this works
None of these frameworks function without the data infrastructure to support them. The 24% of organizations already using enterprise-wide systems report meaningfully fewer standardization problems than the majority still working without one, which is the clearest evidence that KPI tracking is a systems problem before it's a strategy problem.
The organizations closing the gap on R&D productivity aren't the ones spending the most. They're the ones that can actually see, in structured and comparable terms, where their R&D investment is paying off and where it isn't.
.png)
.png)
.png)
